AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at 0.50 micrograms/kg/min
Number of subjects: 10
Study 2506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at 1.00 micrograms/kg/min
Number of subjects: 10
Study 2506503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at 2.00 micrograms/kg/min
Number of subjects: 10
Study 2506503 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 1112210 — intervention group
Group type: EXPERIMENTAL
Intervention: Three drugs (cyclophosphamide, methotrexate, and prednisone) given to 49 patients
Number of subjects: 115
Study 1112210 — intervention group
Group type: EXPERIMENTAL
Intervention: Five drugs (cyclophosphamide, methotrexate, prednisone, vincristine, and 5-fluorouracil) given to 66 patients
Number of subjects: 115
Study 1112210 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (three drugs and five drugs)
Number of subjects: 115
Study 31645293 — intervention group
Group type: EXPERIMENTAL
Intervention: Matriderm®
Number of subjects: 24
Study 31645293 — intervention group
Group type: EXPERIMENTAL
Intervention: Integra®
Number of subjects: 24
Study 30998517 — intervention group
Group type: EXPERIMENTAL
Intervention: B. longum 1714™
Number of subjects: 40
Study 30998517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28282530 — intervention group
Group type: EXPERIMENTAL
Intervention: COPCA (Coping with and Caring for infants with special needs)
Number of subjects: 40
Study 28282530 — intervention group
Group type: COMPARATOR
Intervention: Traditional infant physiotherapy (TIP)
Number of subjects: 40
Study 28282530 — intervention group
Group type: EXPERIMENTAL
Intervention: COPCA
Number of subjects: 40
Study 28282530 — intervention group
Group type: COMPARATOR
Intervention: TIP
Number of subjects: 40
Study 25380801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing at least 6.5×10^9 cfu of Lactobacillus casei strain Shirota (LcS), one bottle/day for 6 weeks
Number of subjects: 40
Study 25380801 — intervention group
Group type: COMPARATOR
Intervention: Placebo, one bottle/day for 6 weeks
Number of subjects: 40
Study 24094567 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat group
Number of subjects: 80
Study 24094567 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery group
Number of subjects: 80
Study 22079192 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF IgG from 2 consecutive lumbar punctures
Number of subjects: 5
Study 22079192 — intervention group
Group type: EXPERIMENTAL
Intervention: Phage peptides
Number of subjects: 5
Study 22079192 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptides recognized by OCBs
Number of subjects: 5
Study 22079192 — intervention group
Group type: EXPERIMENTAL
Intervention: Database search and alanine scan mutagenesis
Number of subjects: 5
Study 19048384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 60
Study 19048384 — intervention group
Group type: COMPARATOR
Intervention: TVT
Number of subjects: 60
Study 16715289 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy (Group II a)
Number of subjects: 520
Study 16715289 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hysteroscopy (Group II b)
Number of subjects: 520
Study 16715289 — intervention group
Group type: COMPARATOR
Intervention: No office hysteroscopy (Group I)
Number of subjects: 520
Study 15237585 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating scheme (3 cycles of 5‐fluorouracil and leucovorin followed by pelvic radiotherapy and 3 weeks after radiation therapy, another 3 cycles of chemotherapy)
Number of subjects: 127
Study 15237585 — intervention group
Group type: COMPARATOR
Intervention: Concomitant scheme (2 cycles of 5‐fluorouracil and leucovorin followed by concurrent radiochemotherapy and 3 weeks after ending, another 2 cycles of 5‐fluorouracil and leucovorin)
Number of subjects: 127
Study 11413440 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 degrees fusion (ALIF + transpedicular instrumentation + PLF)
Number of subjects: 48
Study 11413440 — intervention group
Group type: COMPARATOR
Intervention: 270 degrees fusion (ALIF + transpedicular instrumentation without PLF)
Number of subjects: 48
Study 9409498 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration with 2% lignocaine
Number of subjects: 0
Study 9409498 — intervention group
Group type: COMPARATOR
Intervention: Infiltration with normal saline
Number of subjects: 0
Study 9409498 — intervention group
Group type: COMPARATOR
Intervention: No infiltration
Number of subjects: 0
Study 8359086 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms intravenously)
Number of subjects: 12
Study 8359086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3127220 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose nifedipine
Number of subjects: 9
Study 3127220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained nifedipine therapy (three times daily for five days)
Number of subjects: 9
Study 3127220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 9
Study 3127220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29779821 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (WPS) with dietary counseling (DC)
Number of subjects: 126
Study 29779821 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with dietary counseling (DC)
Number of subjects: 126
Study 27210234 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial manipulation (FM) added to standard care
Number of subjects: 51
Study 24417971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranayama RM training (6 weeks, 5 times/week)
Number of subjects: 54
Study 24417971 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 22742692 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review writing intervention (Share Your Life Story workshop, 8 weeks, once weekly)
Number of subjects: 45
Study 22742692 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 45
Study 20067950 — intervention group
Group type: COMPARATOR
Intervention: Stroke patients walking in a virtual environment (VE) with translational optic flows (OFs) from different directions.
Number of subjects: 21
Study 20067950 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy participants walking in a virtual environment (VE) with translational optic flows (OFs) from different directions.
Number of subjects: 21
Study 20067950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stroke patients and healthy participants) walking in a virtual environment (VE) with translational optic flows (OFs) from different directions.
Number of subjects: 21
Study 18984559 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered intervention
Number of subjects: 190
Study 18984559 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 190
Study 16061320 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrofitted insulation
Number of subjects: 1352
Study 12197863 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview
Number of subjects: 160
Study 12197863 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 160
Study 10983541 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal counselling sessions
Number of subjects: 300
Study 10983541 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal counselling sessions with husbands involved
Number of subjects: 300
Study 7881239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (core temperatures near 34 degrees C)
Number of subjects: 0
Study 7881239 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cooling (core temperatures approaching 32 degrees C)
Number of subjects: 0
Study 7881239 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air cooling method
Number of subjects: 0
Study 7881239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia
Number of subjects: 0
Study 7881239 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rewarming post-hypothermia
Number of subjects: 0
Study 2268740 — intervention group
Group type: EXPERIMENTAL
Intervention: Oyster shell electrolysate (OSE) 900 mg/day
Number of subjects: 12
Study 2268740 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 12
Study 707353 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn supplement
Number of subjects: 20
Study 707353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31825609 — intervention group
Group type: EXPERIMENTAL
Intervention: Debiased data splits
Number of subjects: 0
Study 31825609 — intervention group
Group type: COMPARATOR
Intervention: Randomly split held-out sets
Number of subjects: 0
Study 31825609 — intervention group
Group type: EXPERIMENTAL
Intervention: Debiased data
Number of subjects: 0
Study 30925739 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 108
Study 30925739 — intervention group
Group type: COMPARATOR
Intervention: PVC
Number of subjects: 108
Study 28780466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 (GC80)
Number of subjects: 1363
Study 28780466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 (GC50)
Number of subjects: 1363
Study 28780466 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC6 (GCb6)
Number of subjects: 1363
Study 26037199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinetrol® XPur (900 mg daily for 12 weeks)
Number of subjects: 0
Study 23770157 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 9 μg/kg
Number of subjects: 307
Study 23770157 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 18 μg/kg
Number of subjects: 307
Study 23770157 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 18 μg/kg (re-treated patients)
Number of subjects: 307
Study 23770157 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 18 μg/kg (CD25 low-expression patients)
Number of subjects: 307
Study 23770157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 23770157 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) (patients with capillary leak syndrome)
Number of subjects: 307
Study 23770157 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) (patients without capillary leak syndrome)
Number of subjects: 307
Study 22303710 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole combined with Radix Astragali (Group B)
Number of subjects: 80
Study 22303710 — intervention group
Group type: COMPARATOR
Intervention: Methimazole (Group A)
Number of subjects: 80
Study 22303710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 80
Study 18071342 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid product
Number of subjects: 157
Study 18071342 — intervention group
Group type: COMPARATOR
Intervention: Semi-liquid product
Number of subjects: 157
Study 18071342 — intervention group
Group type: COMPARATOR
Intervention: Semi-solid product
Number of subjects: 157
Study 18071342 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid product (laboratory setting)
Number of subjects: 157
Study 18071342 — intervention group
Group type: COMPARATOR
Intervention: Semi-solid product (laboratory setting)
Number of subjects: 157
Study 18071342 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid product (standardized eating rate)
Number of subjects: 157
Study 18071342 — intervention group
Group type: COMPARATOR
Intervention: Semi-solid product (standardized eating rate)
Number of subjects: 157
Study 18071342 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid product (not controlled)
Number of subjects: 157
Study 18071342 — intervention group
Group type: COMPARATOR
Intervention: Semi-solid product (not controlled)
Number of subjects: 157
Study 16446219 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-Arg9-bradykinin at concentrations of 5.4 x 10(-9), 5.4 x 10(-8), 5.4 x 10(-7), and 1.6 x 10(-6) mol/liter
Number of subjects: 22
Study 16446219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine at concentrations of 10(-8), 10(-7), and 10(-6) mol/liter
Number of subjects: 22
Study 16446219 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no specific intervention mentioned)
Number of subjects: 22
Study 16446219 — intervention group
Group type: COMPARATOR
Intervention: Heart transplant patients (no specific intervention mentioned)
Number of subjects: 22
Study 12639582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 383
Study 12639582 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor surgical procedure
Number of subjects: 383
Study 12639582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medication
Number of subjects: 383
Study 12639582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal intrauterine system
Number of subjects: 383
Study 12639582 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 383
Study 12639582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment preference for hysterectomy
Number of subjects: 383
Study 12639582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment preference for conservative option
Number of subjects: 383
Study 12639582 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing treatment choice
Number of subjects: 383
Study 10708256 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study 9094872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dephytinized infant cereal (0.01% phytic acid)
Number of subjects: 0
Study 9094872 — intervention group
Group type: COMPARATOR
Intervention: Cereal with native phytic acid (0.08% phytic acid)
Number of subjects: 0
Study 1283590 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 240mg once daily
Number of subjects: 20
Study 1283590 — intervention group
Group type: COMPARATOR
Intervention: captopril 25mg twice daily
Number of subjects: 20
Study 3571940 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylamphetamine (15 mg, intravenous)
Number of subjects: 21
Study 3571940 — intervention group
Group type: COMPARATOR
Intervention: Control (sterile water, intravenous)
Number of subjects: 21
Study 31009528 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation behavioral counseling without weight management counseling
Number of subjects: 2540
Study 31009528 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation behavioral counseling with weight management counseling
Number of subjects: 2540
Study 31009528 — intervention group
Group type: COMPARATOR
Intervention: Control calls (counseling calls)
Number of subjects: 2540
Study 31009528 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation pharmacotherapy
Number of subjects: 2540
Study 29364489 — intervention group
Group type: EXPERIMENTAL
Intervention: Hindlimb suspension (HS) for 2 weeks
Number of subjects: 14
Study 29364489 — intervention group
Group type: COMPARATOR
Intervention: Normal control (NC)
Number of subjects: 14
Study 27005405 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 3.0mg
Number of subjects: 359
Study 27005405 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 359
Study 24685072 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Support Intervention (TSI)
Number of subjects: 840
Study 24685072 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Support Intervention + Uterine Artery Doppler Screening (TSI + UADS)
Number of subjects: 840
Study 24685072 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (Control)
Number of subjects: 840
Study 22612463 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group cognitive‐behavioral (FGCB) intervention
Number of subjects: 180
Study 22612463 — intervention group
Group type: COMPARATOR
Intervention: Written information (WI) comparison condition
Number of subjects: 180
Study 20117594 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (assigned shoes based on foot shape)
Number of subjects: 1955
Study 20117594 — intervention group
Group type: COMPARATOR
Intervention: Control group (received stability shoe regardless of plantar shape)
Number of subjects: 1955
Study 16485047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril therapy
Number of subjects: 0
Study 16485047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12851558 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle repositioning maneuver
Number of subjects: 40
Study 11106716 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 microg of peginterferon alfa‐2a once weekly
Number of subjects: 271
Study 11106716 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 microg of peginterferon alfa‐2a once weekly
Number of subjects: 271
Study 11106716 — intervention group
Group type: COMPARATOR
Intervention: 3 million units of interferon alfa‐2a three times weekly
Number of subjects: 271
Study 9053508 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly regimen of IV LV 20 mg/m2 plus bolus 5‐FU 425 mg/m2 for 5 days every 4 weeks
Number of subjects: 433
Study 9053508 — intervention group
Group type: COMPARATOR
Intervention: Bimonthly regimen of IV LV 200 mg/m2 as a 2-hour infusion followed by bolus 5‐FU 400 mg/m2 and 22-hour infusion 5‐FU 600 mg/m2 for 2 consecutive days every 2 weeks
Number of subjects: 433
Study 8372720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucillamine (Bu) 100 mg
Number of subjects: 0
Study 8372720 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucillamine (Bu) 3200 mg (single administration)
Number of subjects: 0
Study 8372720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3606739 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 6027
Study 3606739 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6027
Study 30872330 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent, comprehensive school health program delivered by lay field-workers
Number of subjects: 3033
Study 30872330 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3033
Study 29565771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 10
Study 29565771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-Body Negative Pressure (LBNP)
Number of subjects: 10
Study 29565771 — intervention group
Group type: EXPERIMENTAL
Intervention: α1-receptor blockade via oral prazosin (0.05 mg/kg body wt)
Number of subjects: 10
Study 27734482 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 27734482 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 24232445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 340
Study 24232445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum (St John's wort)
Number of subjects: 340
Study 24232445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 22476569 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition condition, excluding 15 questions
Number of subjects: 270
Study 22476569 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall condition
Number of subjects: 270
Study 22192944 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly visits by Community Health Workers (CHWs)
Number of subjects: 30
Study 22192944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no monthly visits by CHWs)
Number of subjects: 30
Study 18586993 — intervention group
Group type: EXPERIMENTAL
Intervention: BCM care
Number of subjects: 58
Study 18586993 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 17371478 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal A (230 kcal, 0.6 g lipid)
Number of subjects: 24
Study 17371478 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal B (220 kcal, 5 g lipid)
Number of subjects: 24
Study 17371478 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal C (474 kcal, 19 g lipid)
Number of subjects: 24
Study 17371478 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal D (837 kcal, 44 g lipid)
Number of subjects: 24
Study 12928050 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI)
Number of subjects: 141
Study 12928050 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 141
Study 12928050 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 141
Study 10666525 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary pain centre treatment (MPT), n=63
Number of subjects: 189
Study 10666525 — intervention group
Group type: COMPARATOR
Intervention: General practitioner treatment (GP-group), n=63
Number of subjects: 189
Study 10666525 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group (WL-group), n=63
Number of subjects: 189
Study 10666525 — intervention group
Group type: COMPARATOR
Intervention: MPT and GP-groups
Number of subjects: 189
Study 10179602 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized color visual field analysis using 264 colored patches displayed on a PC screen
Number of subjects: 0
Study 10179602 — intervention group
Group type: COMPARATOR
Intervention: Normals
Number of subjects: 0
Study 8378100 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Emotion Induction (PEI)
Number of subjects: 80
Study 8378100 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Relaxation (BR)
Number of subjects: 80
Study 8378100 — intervention group
Group type: COMPARATOR
Intervention: No-instruction (Control)
Number of subjects: 80
Study 8378100 — intervention group
Group type: COMPARATOR
Intervention: Social Demand (Control)
Number of subjects: 80
Study 3730264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 200 micrograms salbutamol and 200 micrograms oxitropium bromide
Number of subjects: 0
Study 3730264 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms salbutamol
Number of subjects: 0
Study 3730264 — intervention group
Group type: COMPARATOR
Intervention: 400 micrograms salbutamol
Number of subjects: 0